Cost-effectiveness of fuzuloparib compared to routine surveillance, niraparib and olaparib for maintenance treatment of patients with germline BRCA1/2 mutation and platinum-sensitive recurrent ovarian carcinoma in China

被引:7
|
作者
Nie, Jing [1 ]
Wu, Huina [1 ]
Sun, Lei [1 ]
Ding, Yanjiao [1 ]
Luan, Yepeng [2 ]
Wu, Jiyong [1 ]
机构
[1] Shandong Second Prov Gen Hosp, Dept Pharm, Jinan, Shandong, Peoples R China
[2] Qingdao Univ, Med Coll, Sch Pharm, Dept Med Chem, Qingdao, Shandong, Peoples R China
关键词
fuzuloparib; niraparib; olaparib; cost-effectiveness; maintenance treatment; ovarian cancer; BRCA1/2; mutation; THERAPY; CANCER; TRIALS;
D O I
10.3389/fphar.2022.987337
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Background: Maintenance therapy with the poly (ADP-ribose) polymerase inhibitors (PARPis) for platinum-sensitive recurrent ovarian carcinoma (OC) have proven to be effective compared with placebo. We aimed to evaluate the cost-effectiveness (CE) of maintenance fuzuloparib compared to routine surveillance (RS), niraparib and olaparib for platinum-sensitive recurrent OC from the Chinese healthcare systems.Method: A partitioned survival model with three-state (progression-free, progressed, death) was constructed utilizing TreeAge Pro 2011 software to evaluate the economic value of fuzuloparib, niraparib and olaparib maintenance treatment for platinum-sensitive recurrent OC based on the clinical data derived from FZOCUS-2, ENGOT-OV16/NOVA and ENGOT-Ov21/SOLO2. Transition probabilities were estimated from the reported survival probabilities in those trials. Cost and health preference data were derived from the literature. The quality-adjusted life-years (QALYs) and lifetime costs were measured for this analysis. A 5 years horizon and 5%/year discount rates were used. One-way analysis, and probabilistic sensitivity analysis (PSA) were performed to explore the model uncertainties.Results: Total cost of fuzuloparib, niraparib and olaparib were $31628.10, $48183.48 and $54605.54, whereas they had an incremental cost-utility ratio of $31992.69, $32216.08 and $23359.26 per additional progression-free survival (PFS) QALYs gained compared with RS, relatively. Model showed that maintenance fuzuloparib achieved at least an 85.5% probability of CE at the threshold of $37654.50/QALY. One-way sensitivity analysis revealed that the results were sensitive to the PFS and the price of medicines.Conclusion: Fuzuloparib was less cost-effective for patients with germline BRCA1/2 mutation and platinum-sensitive recurrent OC compared to olaparib, but was superior to niraparib from the Chinese healthcare systems perspective.
引用
收藏
页数:8
相关论文
共 50 条
  • [21] Olaparib not cost-effective as maintenance therapy for platinum-sensitive, BRCA1/2 germline-mutated metastatic pancreatic cancer
    Mehra, Tarun
    Lupatsch, Judith E.
    Kossler, Thibaud
    Dedes, Konstantin
    Siebenhuner, Alexander Reinhard
    von Moos, Roger
    Wicki, Andreas
    Schwenkglenks, Matthias E.
    PLOS ONE, 2024, 19 (04):
  • [22] Response to "Comment on "Cost-Effectiveness of Niraparib Versus Routine Surveillance, Olaparib and Rucaparib for the Maintenance Treatment of Patients with Ovarian Cancer in the United States"'
    Guy, Holly
    Walder, Lydia
    Fisher, Mark
    PHARMACOECONOMICS, 2019, 37 (07) : 965 - 967
  • [23] Response to ‘Comment on “Cost-Effectiveness of Niraparib Versus Routine Surveillance, Olaparib and Rucaparib for the Maintenance Treatment of Patients with Ovarian Cancer in the United States”’
    Holly Guy
    Lydia Walder
    Mark Fisher
    PharmacoEconomics, 2019, 37 : 965 - 967
  • [24] Cost-effectiveness of niraparib versus routine surveillance, olaparib, and rucaparib for the maintenance treatment of adult patients with ovarian cancer in the United States.
    Fisher, Mark
    Guy, Holly
    Walder, Lydia
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [25] Cost-Effectiveness Analysis of Maintenance Olaparib in Patients with Metastatic Pancreatic Cancer and a Germline BRCA1/2 Mutation Based on the POLO Trial
    Zhan, Mei
    Zheng, Hanrui
    Yang, Yu
    He, Zhiyao
    Xu, Ting
    Li, Qiu
    CANCER MANAGEMENT AND RESEARCH, 2020, 12 : 12919 - 12926
  • [26] ESTIMATING THE MEAN PROGRESSION-FREE SURVIVAL OF NIRAPARIB, OLAPARIB AND RUCAPARIB COMPARED TO ROUTINE SURVEILLANCE FOR THE MAINTENANCE TREATMENT OF ADULT PATIENTS WITH RECURRENT OVARIAN CANCER WITHOUT A BRCA MUTATION
    Fisher, M.
    Guy, H.
    Walder, L.
    VALUE IN HEALTH, 2018, 21 : S21 - S21
  • [27] NICE guidance on olaparib for maintenance treatment of patients with relapsed, platinum-sensitive, BRCA mutation-positive ovarian cancer
    Tucker, Helen
    Charles, Zoe
    Robertson, Janet
    Adam, Jane
    LANCET ONCOLOGY, 2016, 17 (03): : 277 - 278
  • [28] Maintenance olaparib monotherapy for platinum-sensitive relapsed ovarian cancer in patients without a germline BRCA1/BRCA2 mutation: Secondary safety results from the phase IIIb OPINION study
    Colombo, Nicoletta
    Madry, Radoslaw
    Skof, Erik
    Weberpals, Johanne
    Blakeley, Chris
    Marshall, Helen
    Brickel, Neil
    Poveda, Andres
    GYNECOLOGIC ONCOLOGY, 2022, 166 : S81 - S82
  • [29] Cost-Effectiveness of Adjuvant Olaparib for Patients With Breast Cancer and Germline BRCA1/2 Mutations
    Zettler, Christina M.
    De Silva, Dilanka L.
    Blinder, Victoria S.
    Robson, Mark E.
    Elkin, Elena B.
    JAMA NETWORK OPEN, 2024, 7 (01)
  • [30] PARP inhibitor maintenance therapy for patients with platinum-sensitive recurrent ovarian cancer: A cost-effectiveness analysis
    Smith, Haller J.
    Haygood, Christen L. Walters
    Arend, Rebecca C.
    Leath, Charles A., III
    Straughn, Michael, Jr.
    GYNECOLOGIC ONCOLOGY, 2015, 139 (01) : 59 - 62